Cogent reports Q3 2026 results, three bezuclastinib PDUFA dates ahead
Cogent says it is ready to launch bezuclastinib in GIST pending a November 30, 2026 FDA decision, with two more PDUFA dates and $791.1 million in cash into late 2028.
SEC filing
2 stories
Cogent says it is ready to launch bezuclastinib in GIST pending a November 30, 2026 FDA decision, with two more PDUFA dates and $791.1 million in cash into late 2028.
SEC filing
The agreement, dated September 1, 2026, covers manufacturing of bezuclastinib's spray-dried dispersion and tablet forms.
SEC filing